Literature DB >> 8763043

Cerebellar lithium toxicity: a review of recent literature and tentative pathophysiology.

S Grignon1, B Bruguerolle.   

Abstract

Lithium is the archetype of mood stabilizing drugs. Its narrow therapeutic index mostly accounts for the occurrence of acute intoxications. There is, however, growing evidence that lithium can induce long lasting neurological sequelae. These appear to be multifactorial, resulting mainly from overdosage, concomitant neuroleptic treatment, and hyperthermia. The most frequent clinical feature is a permanent cerebellar syndrome. As regards the few pathological data available, there is a striking loss of cerebellar Purkinje cells, which is present in all published neuropathological reports on this condition. It is suggested that lithium, cytokines, and neuroleptics synergize to disrupt calcium homeostasis in Purkinje cells, and to elicit calcium-mediated neurotoxicity. This model might help predict high risk clinical situations and define useful working hypotheses as well.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763043

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  8 in total

1.  Lithium chloride therapy fails to improve motor function in a transgenic mouse model of Machado-Joseph disease.

Authors:  Sara Duarte-Silva; Andreia Neves-Carvalho; Carina Soares-Cunha; Andreia Teixeira-Castro; Pedro Oliveira; Anabela Silva-Fernandes; Patrícia Maciel
Journal:  Cerebellum       Date:  2014-12       Impact factor: 3.847

Review 2.  Permanent Cerebellar Degeneration After Acute Hyperthermia with Non-toxic Lithium Levels: a Case Report and Review of Literature.

Authors:  Fabian H Rossi; Elisa Marie Rossi; Michael Hoffmann; Welwin Liu; Ramon Rodriguez Cruz; Natasha Antonovich; Arash Rezaei; Elizabeth Gonzalez; Maria Clara Franco; Alvaro Estevez; Florian Thomas
Journal:  Cerebellum       Date:  2017-12       Impact factor: 3.847

3.  Lithium toxicity in yeast is due to the inhibition of RNA processing enzymes.

Authors:  B Dichtl; A Stevens; D Tollervey
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

Review 4.  Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1.

Authors:  Serena Notartomaso; Cristina Zappulla; Francesca Biagioni; Milena Cannella; Domenico Bucci; Giada Mascio; Pamela Scarselli; Francesco Fazio; Filippo Weisz; Luana Lionetto; Maurizio Simmaco; Roberto Gradini; Giuseppe Battaglia; Michele Signore; Aldamaria Puliti; Ferdinando Nicoletti
Journal:  Mol Brain       Date:  2013-11-19       Impact factor: 4.041

6.  A case of skew deviation and downbeat Nystagmus induced by Lithium.

Authors:  Hyunkyu Hong; In Jeong Lyu
Journal:  BMC Ophthalmol       Date:  2019-12-16       Impact factor: 2.209

7.  Abnormalities in brain structure and behavior in GSK-3alpha mutant mice.

Authors:  Oksana Kaidanovich-Beilin; Tatiana V Lipina; Keizo Takao; Matthijs van Eede; Satoko Hattori; Christine Laliberté; Mustafa Khan; Kenichi Okamoto; John W Chambers; Paul J Fletcher; Katrina MacAulay; Bradley W Doble; Mark Henkelman; Tsuyoshi Miyakawa; John Roder; James R Woodgett
Journal:  Mol Brain       Date:  2009-11-19       Impact factor: 4.041

8.  Persistent cerebellar dysfunction following acute lithium toxicity: A report of two cases.

Authors:  Girish Banwari; Pradhyuman Chaudhary; Ankit Panchmatia; Nisheet Patel
Journal:  Indian J Pharmacol       Date:  2016 May-Jun       Impact factor: 1.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.